|Articles|November 8, 2022
- Pharmaceutical Executive-11-01-2022
- Volume 42
- Issue 11
Pharmaceutical Executive, November 2022 Issue (PDF)
Advertisement
Articles in this issue
almost 4 years ago
Labs and Computing Power: The Missing Link for a Revolution by 2030almost 4 years ago
A Culture of Quality: The Catalyst to Accelerate Innovationalmost 4 years ago
A Mission of the Heartalmost 4 years ago
The New Reality for Industry Dealmaking May be Setting Inalmost 4 years ago
Is ESG a ‘Protection Racket’ or Long-Term Value Contributor?almost 4 years ago
Digital Biomarkers Could Reshape CNS Diagnosis, Treatmentalmost 4 years ago
Long-Sought Reforms To EU Drug Rules Hit A Snag—What Now?almost 4 years ago
Recaps, Live & In Personalmost 4 years ago
FDA Keeps Its User Fees, but Fails to Gain Important ReformsAdvertisement
Advertisement
Advertisement
Trending on PharmExec
1
Trump Administration Preparing New Round of Medicaid Drug-Pricing Deals: Report
2
M&A Roundup: DualityBio & Genentech Enter Partnership to Develop Next Generation ADC’s, Teva Bids to Acquire Igalmi from BioXcel
3
Study Shows Link Between Zepbound and Lower Healthcare Costs in Adults Aged 55 and Up with Obesity: Report
4
Pharmaceutical Executive Daily: DualityBio and Teva Strike Major Biopharma Deals
5

